Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma
(January 25, 2018)
CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential... Continue Reading
FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma
(January 5, 2018)
CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma... Continue Reading
Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer
(November 9, 2017)
Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to... Continue Reading
FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma
(June 19, 2017)
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy. ... Continue Reading
Dalantercept- Inlyta Shows Promise for Renal Cell Cancer
(March 1, 2017)
The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment of advanced renal cell carcinoma (RCC) according to the results of a recently published Phase I clinical... Continue Reading
Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer
(December 5, 2016)
The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical... Continue Reading
Lenvima® Approved for Kidney Cancer
(May 24, 2016)
The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic... Continue Reading
Cabometyx® Approved for Kidney Cancer
(May 10, 2016)
The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already... Continue Reading
Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide
(March 15, 2016)
If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and... Continue Reading
FDA Approves Opdivo for Renal Cell Carcinoma
(November 25, 2015)
The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung... Continue Reading
Latest Renal Cancer News By Stage
General Renal Cancer
Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer
(December 5, 2016)
The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical... Continue Reading
Lenvima® Approved for Kidney Cancer
(May 24, 2016)
The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic... Continue Reading
Cabometyx® Approved for Kidney Cancer
(May 10, 2016)
The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already... Continue Reading
Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide
(March 15, 2016)
If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and... Continue Reading
FDA Approves Opdivo for Renal Cell Carcinoma
(November 25, 2015)
The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung... Continue Reading
More General Renal Cancer